In taking the type 2 diabetes medication Farxiga (dapagliflozin) could give years of life to those suffering from a common type of heart disease, as per an article that was published in JAMA Cardiology.
Although Farxiga was originally designed in order to help treat diabetes type 2, it was studied — and then approved to treat other health issues, too. In May of 2020 the drug was granted approval by the U.S. Food and Drug Administration (FDA) for use as an option for treating heart failure and a lower ejection fraction, irrespective of whether the patient suffers from diabetes. Then , in April 2021 Farxiga was approved as a remedy for chronic kidney disease after clinical trials that were stopped early due to the fact that they proved an “overwhelming” positive effect in this condition.
Click here for a Farxiga coupon.
The benefits of Farxiga’s Heart failure
Researchers have demonstrated that, based on the results of the clinical trial of people suffering from heart disease It’s likely that taking Farxiga could bring years of life to those suffering from this disease — the result was calculated from the data, rather than demonstrated, as the trial isn’t for long enough to demonstrate that the medication adds years of living. In this “exploratory study,” researchers looked at the data from a study of 474 patients with heart failure that were randomly assigned to one of two drugs: Farxiga and a placebo (inactive pills). Participants were enrolled from February 2017 to August 2018 and were monitored through June 2019 with an average time that was 17.6 months.
For those who were given Farxiga in the course in the research, 10 milligrams the drug were administered once every day as an additional regular therapy for patients suffering from heart failure. The main outcome that researchers were seeking was the length of duration until patients required hospitalization or an urgent-care appointment that required IV (IV) treatments for heart failure or until they passed away from heart-related causes. Based on the findings of other studies that have revealed about the connection between hospitalization due to heart failure and death due to cardiovascular causes or any other cause they then used the information on Farxiga to calculate how long people could have to live if taking the medication for the rest of their lives.
Researchers discovered that a person aged 65 who suffers from heart failure could be likely to live for an additional 6.2 years without experiencing a cardiovascular incident if they used the placebo, as well as an extra 8.3 years should they used Farxiga. If they examined deaths from any cause in the study, the median survival time for a 65-year-old who took an placebo was calculated as 9.1 years. For Farxiga this was 10.8 years. This is more than 1.7 year of living. Similar results were found when the researchers calculated the results for individuals with different ages.
“These results suggest that [Farxiga] can provide beneficial clinical outcomes in extrapolating life expectancy and event-free,” the researchers wrote. “These results could be useful in promoting the advantages of this treatment” to patients suffering from heart failure.